Singapore, Oct. 7 -- Qiagen has announced new artificial intelligence (AI) capabilities to help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible.

The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows.

The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights (QDI), whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25...